Mabylon
Mabylon is a biotechnology company focused on developing innovative antibody-based therapies for infectious diseases and cancer.
About
Mabylon AG is a clinical-stage biotechnology company focused on discovering and engineering novel antibody therapeutics for allergy, inflammation, and neurology. They leverage a technology platform that rapidly identifies and clones human-derived or immunized animal antibodies from diverse immune repertoires. Mabylon aims to select the best functional, therapeutically relevant antibody products to address unmet medical needs in these areas. Teams look it up for Biotech, MedTech, Drug Discovery.
Frequently asked
What does Mabylon do?
Mabylon is a Biotech company that offers Platform. Teams look it up for MedTech, Drug Discovery, Antibody Therapeutics. It is based in Geneva, Switzerland. Public records show $36M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Mabylon raised?
Mabylon has raised a total of $36M in funding. The most recent round on record is Series A.
Where is Mabylon headquartered?
Mabylon is headquartered in Geneva, Switzerland.
What industry does Mabylon operate in?
Mabylon operates in Biotech, MedTech, Drug Discovery, Antibody Therapeutics, Infectious Disease.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.